Inhibiting the mitochondrial pyruvate carrier does not ameliorate synucleinopathy in the absence of inflammation or metabolic deficits

MLA

Wouter Peelaerts, et al. “Inhibiting the Mitochondrial Pyruvate Carrier Does Not Ameliorate Synucleinopathy in the Absence of Inflammation or Metabolic Deficits.” Free Neuropathology, vol. 1, Nov. 2020, p. 33. EBSCOhost, https://doi.org/10.17879/freeneuropathology-2020-3049.

APA

Wouter Peelaerts, Liza Bergkvist, Sonia George, Michaela Johnson, Lindsay Meyerdirk, Emily Schulz, Jennifer A. Steiner, Zachary Madaj, Jiyan Ma, Katelyn Becker, K. Peter R. Nilsson, Jerry R. Colca, & Patrik Brundin. (2020). Inhibiting the mitochondrial pyruvate carrier does not ameliorate synucleinopathy in the absence of inflammation or metabolic deficits. Free Neuropathology, 1, 33. https://doi.org/10.17879/freeneuropathology-2020-3049

Chicago

Wouter Peelaerts, Liza Bergkvist, Sonia George, Michaela Johnson, Lindsay Meyerdirk, Emily Schulz, Jennifer A. Steiner, et al. 2020. “Inhibiting the Mitochondrial Pyruvate Carrier Does Not Ameliorate Synucleinopathy in the Absence of Inflammation or Metabolic Deficits.” Free Neuropathology 1 (November): 33. doi:10.17879/freeneuropathology-2020-3049.